Quantcast

Old North News

Thursday, September 19, 2024

FDA conducted second highest number of inspections on Biologics companies in North Carolina during Q1

Webp 2ezm6a5laa3vullezt9gk0ym96qi

Leah Hunter Commissioner for External Affairs (OEA) within the Office of the Commissioner at the U.S. Food and Drug Administration | Official Website

Leah Hunter Commissioner for External Affairs (OEA) within the Office of the Commissioner at the U.S. Food and Drug Administration | Official Website

In the first quarter of 2024, four Biologics companies received four FDA inspections in North Carolina, according to the U.S. Food and Drug Administration (FDA).

This was the second highest number of inspections per type of company made by the FDA in North Carolina, equalling 20% of all inspections in the first quarter of 2024.

Of all the North Carolina companies involved in the Biologics sector, Cone Health received the most citations from the FDA in the first quarter of 2024.

The FDA routinely inspects facilities across the nation to determine if the workplaces and their products are compliant with FDA-regulated laws and regulations implemented to improve overall public health. Inspection results are then disclosed publicly for businesses to consistently make smarter business decisions for the future.

The FDA is a government agency primarily responsible for monitoring the manufacturing and distribution of human and animal drugs, biological products, medical supplies and tobacco products for safety quality, according to its website.

FDA Inspections in North Carolina During Q1
Project AreaNo Action IndicatedVoluntary Action IndicatedOfficial Action Indicated
Bioresearch Monitoring1----
Blood and Blood Products31--
Compliance: Devices21--
Drug Quality Assurance111
Food Composition, Standards, Labeling and Econ11--
Foodborne Biological Hazards52--
Human Cellular, Tissue, and Gene Therapies1----
Postmarket Assurance: Devices1----
Technical Assistance: Food and Cosmetics2----

MORE NEWS